- Home
- AOMR vs AVIR Comparison
AOMR vs AVIR Comparison
Compare AOMR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- AVIR
- Stock Information
- Founded
- AOMR 2018
- AVIR 2012
- Country
- AOMR United States
- AVIR United States
- Employees
- AOMR N/A
- AVIR N/A
- Industry
- AOMR Real Estate Investment Trusts
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- AOMR Real Estate
- AVIR Health Care
- Exchange
- AOMR Nasdaq
- AVIR Nasdaq
- Market Cap
- AOMR 240.9M
- AVIR 276.9M
- IPO Year
- AOMR 2021
- AVIR 2020
- Fundamental
- Price
- AOMR $9.81
- AVIR $3.22
- Analyst Decision
- AOMR Buy
- AVIR Hold
- Analyst Count
- AOMR 6
- AVIR 1
- Target Price
- AOMR $12.10
- AVIR $6.88
- AVG Volume (30 Days)
- AOMR 119.1K
- AVIR 175.5K
- Earning Date
- AOMR 11-06-2024
- AVIR 11-07-2024
- Dividend Yield
- AOMR 13.06%
- AVIR N/A
- EPS Growth
- AOMR N/A
- AVIR N/A
- EPS
- AOMR 2.91
- AVIR N/A
- Revenue
- AOMR $94,441,000.00
- AVIR N/A
- Revenue This Year
- AOMR N/A
- AVIR N/A
- Revenue Next Year
- AOMR $29.25
- AVIR N/A
- P/E Ratio
- AOMR $3.37
- AVIR N/A
- Revenue Growth
- AOMR 455.18
- AVIR N/A
- 52 Week Low
- AOMR $8.88
- AVIR $2.77
- 52 Week High
- AOMR $13.32
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- AOMR 52.63
- AVIR 39.98
- Support Level
- AOMR $9.80
- AVIR $3.32
- Resistance Level
- AOMR $10.11
- AVIR $3.48
- Average True Range (ATR)
- AOMR 0.22
- AVIR 0.14
- MACD
- AOMR 0.11
- AVIR -0.01
- Stochastic Oscillator
- AOMR 75.20
- AVIR 9.09
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).